ADMA
ADMA Biologics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Beats Expectation
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ADMA
Adma Biologics, Inc.
A company that develops specialty plasma-based biologics for the treatment and prevention of infectious diseases
465 State Route 17, Ramsey, New Jersey 07446
--
ADMA Biologics, Inc., was incorporated in New Jersey on June 24, 2004. The Company is an end-to-end commercial biopharmaceutical company that manufactures, markets and develops specialized biologics for the treatment of immunodeficient patients at risk of infection and others at risk of specific infectious diseases. The company's target patient population includes immune-impaired individuals with underlying immunodeficiency diseases or who may be immunosuppressed for medical reasons.
Earnings Call
Q1/2025
Estimate EPS0.14
Actual EPS0.14
Estimate Revenue118.65M
Actual Revenue114.80M
ADMA Biologics Q1 2025: Navigating Contradictions in Supply Strategies and Demand Dynamics
May 07,2025 11:06
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.14
Actual EPS0.14
Estimate Revenue121.77M
Actual Revenue121.98M
ADMA Biologics' Q2 2025: Unraveling Contradictions in Yield Enhancements, Reimbursement, and Demand Dynamics
Aug 06,2025 09:25
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ADMA has released its 2025 Q3 earnings. EPS was reported at 0.15, versus the expected 0.16, missing expectations. The chart below visualizes how ADMA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ADMA has released its 2025 Q3 earnings report, with revenue of 134.22M, reflecting a YoY change of 12.00%, and net profit of 36.43M, showing a YoY change of 1.45%. The Sankey diagram below clearly presents ADMA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
